Market Predictions
Thread 5 — Oncology US market · with explainability
190 predictions
LR CV AUC 0.884
Updated 2026-04-04
← Market KG ← Overview
Model limitations — read before interpreting predictions
This week's analysis
Model Review Agent · 2026-04-04

This week's prediction run covers 190 drug-indication pairs across 4 models. The approval model (CV AUC 0.88) shows near-uniform high probabilities due to label construction — interpret as relative ranking rather than calibrated probabilities. The disruption model correctly identifies shortage-adjacent drugs (bortezomib, nivolumab, carfilzomib) as high-risk, though it lacks ground truth validation. Revenue trajectory indices cluster tightly (4.0-10.0) and should be used directionally only given CMS data lag. Feature completeness averages 49%, with NIH funding, patent cliff, and policy risk entirely null — these represent the highest-value enrichment opportunities. Tier 2 correctly identified nih_funding_momentum as the most valuable missing feature, proposing 25 edges across pembrolizumab, nivolumab, atezolizumab, and durvalumab.

Notable signals
BORTEZOMIB Multiple Myeloma disruption risk score 100.0% Highest disruption risk in dataset. Driven by shortage_risk_score=2 (actual FDA shortage) combined with regulatory momentum. Plausible high-risk signal.
NIVOLUMAB Multiple indications disruption risk score 98.7% Consistent high disruption risk across 7 indications due to shortage_risk_score=2. Model correctly flags supply chain vulnerability.
DOCETAXEL Breast Cancer approval probability 100.0% Ceiling effect — all approval probabilities near 1.0. Not a meaningful prediction due to label contamination from post-2018 approval definition.
CARFILZOMIB Multiple Myeloma disruption risk score 100.0% High disruption driven by shortage_risk. Multiple Myeloma shows concentrated high-risk signals among 3 drugs (bortezomib, lenalidomide, carfilzomib).
ENZALUTAMIDE Prostate Cancer approval probability 100.0% Slightly lower than others (regulatory_momentum=5 vs 10). Still near-ceiling, demonstrating model's limited discrimination for approval probability.
Feature improvement proposals
nih funding momentum usd per yr medium

100% null in current run but identified by Tier 2 as highest-priority enrichment. NIH RePORTER API (https://api.reporter.nih.gov) provides grant funding by drug/indication keyword. Would enable research momentum signal for all 190 predictions.

patent cliff proximity yrs low

100% null. FDA Orange Book data files (https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files) provide patent expiry dates. Critical for revenue trajectory modeling and generic competition timing.

trial start date medium

Not in current feature matrix. ClinicalTrials.gov API can provide trial start dates. Required to convert empirical approval year distributions into true development duration estimates for timing model.

190
Drug × indication pairs
190
Training rows (approval model)
0.884
Logistic CV AUC (5-fold)
Yes
Disruption RF trained
Data freshness by vertical
VerticalSourceCadence
Academic research PubMed · NIH Reporter weekly
Drug discovery ChEMBL · Open Targets weekly
Trials Thread 2 cross-ref daily
FDA regulatory openFDA Drugs@FDA weekly
Sales (CMS) CMS Part D 2yr lag — amber always
Manufacturing openFDA enforcement weekly
Distribution HRSA 340B weekly
Government policy Fed Register · Congress weekly
Model metadata
Approval probability
LogisticRegression(C=1.0, L2)
Label = 1 if drug has any approval post-2018, 0 otherwise. In-sample split — not an external held-out dataset. CV AUC is indicative only.
Revenue trajectory index
Ridge(alpha=1.0)
CMS Part D data has 2yr lag. Treat output as directional index only.
Disruption risk
RandomForestClassifier(n_estimators=50, max_depth=4)
Labels constructed from observable KG signals (shortage + competitive entry). No validated ground truth.
Market entry timing
Empirical approval year distribution per indication
Distribution of approval years, not trial duration. Trial start dates not yet in KG.
Filter:
Drug ↕ Indication ↕ Approval prob ↕ Disruption risk ↕ Revenue index ↕ Approval yr (median) ↕ Data completeness ↕
LENALIDOMIDE
 Diffuse Large B-Cell Lymphoma 100.0%
100.0–100.0%
 91.5% 9.96 2023 (n=15) 56% ▸
AKEEGA
ABIRATERONE ACETATE
 Ovarian Cancer 100.0%
100.0–100.0%
 98.8% 9.96 2020 (n=39) 44% ▸
AKEEGA
ABIRATERONE ACETATE
 Prostate Cancer 100.0%
100.0–100.0%
 100.0% 9.96 2022 (n=33) 44% ▸
LENALIDOMIDE
 Chronic Lymphocytic Leukemia 100.0%
100.0–100.0%
 98.8% 9.96 2023 (n=20) 44% ▸
LENALIDOMIDE
 Multiple Myeloma 100.0%
100.0–100.0%
 92.4% 9.96 2022 (n=29) 44% ▸
BORTEZOMIB
 Multiple Myeloma 100.0%
100.0–100.0%
 100.0% 9.96 2022 (n=29) 44% ▸
JEVTANA KIT
CABAZITAXEL
 Prostate Cancer 100.0%
100.0–100.0%
 100.0% 7.97 2022 (n=33) 44% ▸
DOCETAXEL
 Breast Cancer 100.0%
100.0–100.0%
 88.7% 9.95 2022 (n=61) 44% ▸
DOCETAXEL
 Gastric Cancer 100.0%
100.0–100.0%
 100.0% 9.96 2020 (n=66) 44% ▸
DOCETAXEL
 Head and Neck Cancer 100.0%
100.0–100.0%
 98.8% 9.96 2023 (n=21) 44% ▸
DOCETAXEL
 Prostate Cancer 100.0%
100.0–100.0%
 100.0% 9.96 2022 (n=33) 44% ▸
DOCETAXEL
 Non-Small Cell Lung Cancer 100.0%
100.0–100.0%
 87.5% 9.96 2020 (n=48) 44% ▸
PACLITAXEL
 Ovarian Cancer 100.0%
100.0–100.0%
 98.8% 8.97 2020 (n=39) 44% ▸
PACLITAXEL
 Breast Cancer 100.0%
100.0–100.0%
 88.7% 8.96 2022 (n=61) 44% ▸
PACLITAXEL
 Gastric Cancer 100.0%
100.0–100.0%
 100.0% 8.97 2020 (n=66) 44% ▸
PACLITAXEL
 Non-Small Cell Lung Cancer 100.0%
100.0–100.0%
 87.5% 8.96 2020 (n=48) 44% ▸
IRINOTECAN HYDROCHLORIDE
 Colorectal Cancer 100.0%
100.0–100.0%
 98.8% 7.97 2020 (n=47) 44% ▸
OXALIPLATIN
 Colorectal Cancer 100.0%
100.0–100.0%
 98.8% 9.96 2020 (n=47) 44% ▸
OXALIPLATIN
 Gastric Cancer 100.0%
100.0–100.0%
 100.0% 9.96 2020 (n=66) 44% ▸
GEMZAR
GEMCITABINE HYDROCHLORIDE
 Ovarian Cancer 100.0%
100.0–100.0%
 98.8% 8.97 2020 (n=39) 44% ▸
GEMZAR
GEMCITABINE HYDROCHLORIDE
 Bladder Cancer 100.0%
100.0–100.0%
 89.8% 8.96 2019 (n=14) 44% ▸
GEMZAR
GEMCITABINE HYDROCHLORIDE
 Pancreatic Cancer 100.0%
100.0–100.0%
 98.8% 8.97 2015 (n=9) 44% ▸
GEMZAR
GEMCITABINE HYDROCHLORIDE
 Non-Small Cell Lung Cancer 100.0%
100.0–100.0%
 87.5% 8.96 2020 (n=48) 44% ▸
XELODA
CAPECITABINE
 Breast Cancer 100.0%
100.0–100.0%
 88.7% 9.95 2022 (n=61) 44% ▸
XELODA
CAPECITABINE
 Colorectal Cancer 100.0%
100.0–100.0%
 98.8% 9.96 2020 (n=47) 44% ▸
XELODA
CAPECITABINE
 Gastric Cancer 100.0%
100.0–100.0%
 100.0% 9.96 2020 (n=66) 44% ▸
XTANDI
ENZALUTAMIDE
 Prostate Cancer 100.0%
100.0–100.0%
 100.0% 4.99 2022 (n=33) 44% ▸
OPDUALAG
NIVOLUMAB
 Hepatocellular Carcinoma 100.0%
100.0–100.0%
 98.7% 4.99 2022 (n=14) 44% ▸
OPDUALAG
NIVOLUMAB
 Head and Neck Cancer 100.0%
100.0–100.0%
 100.0% 4.99 2023 (n=21) 44% ▸
OPDUALAG
NIVOLUMAB
 Gastric Cancer 100.0%
100.0–100.0%
 100.0% 4.99 2020 (n=66) 44% ▸
OPDUALAG
NIVOLUMAB
 Melanoma 100.0%
100.0–100.0%
 98.7% 4.99 2022 (n=8) 44% ▸
OPDUALAG
NIVOLUMAB
 Colorectal Cancer 100.0%
100.0–100.0%
 100.0% 4.99 2020 (n=47) 44% ▸
OPDUALAG
NIVOLUMAB
 Renal Cell Carcinoma 100.0%
100.0–100.0%
 100.0% 4.99 2022 (n=13) 44% ▸
OPDUALAG
NIVOLUMAB
 Non-Small Cell Lung Cancer 100.0%
100.0–100.0%
 98.7% 4.99 2020 (n=48) 44% ▸
CARFILZOMIB
 Multiple Myeloma 100.0%
100.0–100.0%
 100.0% 4.99 2022 (n=29) 44% ▸
IMBRUVICA
IBRUTINIB
 Chronic Lymphocytic Leukemia 99.9%
99.8–99.9%
 98.8% 3.99 2023 (n=20) 44% ▸
FLUOROURACIL
 Breast Cancer 99.3%
99.1–99.5%
 72.7% 2.99 2022 (n=61) 44% ▸
FLUOROURACIL
 Gastric Cancer 99.3%
99.0–99.5%
 96.0% 3.00 2020 (n=66) 44% ▸
FLUOROURACIL
 Colorectal Cancer 99.2%
98.9–99.5%
 98.8% 3.00 2020 (n=47) 44% ▸
FLUOROURACIL
 Head and Neck Cancer 99.2%
99.0–99.5%
 98.8% 3.00 2023 (n=21) 44% ▸
PALBOCICLIB
 Breast Cancer 96.2%
95.0–97.4%
 6.7% 2.00 2022 (n=61) 44% ▸
VERZENIO
ABEMACICLIB
 Breast Cancer 96.2%
94.8–97.5%
 6.7% 2.00 2022 (n=61) 44% ▸
LYNPARZA
OLAPARIB
 Breast Cancer 96.2%
94.8–97.2%
 6.7% 2.00 2022 (n=61) 44% ▸
LYNPARZA
OLAPARIB
 Ovarian Cancer 95.8%
94.2–97.1%
 16.4% 2.00 2020 (n=39) 44% ▸
ZEJULA
NIRAPARIB TOSYLATE
 Ovarian Cancer 95.8%
93.8–96.8%
 16.4% 2.00 2020 (n=39) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Breast Cancer 95.5%
93.6–96.7%
 90.0% 2.00 2022 (n=61) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Bladder Cancer 95.3%
93.2–96.7%
 100.0% 2.00 2019 (n=14) 44% ▸
TECENTRIQ
ATEZOLIZUMAB
 Bladder Cancer 95.3%
93.5–96.7%
 100.0% 2.00 2019 (n=14) 44% ▸
RITUXAN
RITUXIMAB
 Diffuse Large B-Cell Lymphoma 95.3%
93.5–96.8%
 99.5% 2.00 2023 (n=15) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Hepatocellular Carcinoma 95.2%
93.5–96.4%
 98.7% 2.00 2022 (n=14) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Melanoma 95.2%
92.9–96.5%
 98.7% 2.00 2022 (n=8) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Non-Small Cell Lung Cancer 95.2%
93.4–96.6%
 98.7% 2.00 2020 (n=48) 44% ▸
TECENTRIQ
ATEZOLIZUMAB
 Non-Small Cell Lung Cancer 95.2%
93.5–96.6%
 98.7% 2.00 2020 (n=48) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Gastric Cancer 95.1%
93.2–96.5%
 97.5% 2.00 2020 (n=66) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Head and Neck Cancer 95.0%
93.1–96.5%
 93.7% 2.00 2023 (n=21) 44% ▸
KEYTRUDA
PEMBROLIZUMAB
 Colorectal Cancer 95.0%
93.0–96.5%
 93.7% 2.00 2020 (n=47) 44% ▸
RITUXAN
RITUXIMAB
 Chronic Lymphocytic Leukemia 95.0%
93.1–96.4%
 93.7% 2.00 2023 (n=20) 44% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Breast Cancer 81.6%
75.6–86.4%
 2.8% 1.00 2022 (n=61) 44% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Breast Cancer 81.6%
75.1–86.7%
 2.8% 1.00 2022 (n=61) 44% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Breast Cancer 81.6%
75.8–86.0%
 2.8% 1.00 2022 (n=61) 44% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Breast Cancer 81.6%
74.9–87.2%
 2.8% 1.00 2022 (n=61) 44% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Breast Cancer 81.6%
75.6–86.4%
 2.8% 1.00 2022 (n=61) 44% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Breast Cancer 81.6%
75.5–86.6%
 2.8% 1.00 2022 (n=61) 44% ▸
HERCESSI
TRASTUZUMAB-STRF
 Breast Cancer 81.6%
75.6–86.7%
 2.8% 1.00 2022 (n=61) 44% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Breast Cancer 81.6%
74.9–86.8%
 2.8% 1.00 2022 (n=61) 44% ▸
OGIVRI
TRASTUZUMAB-DKST
 Breast Cancer 81.6%
75.9–86.8%
 2.8% 1.00 2022 (n=61) 44% ▸
POHERDY
PERTUZUMAB-DPZB
 Breast Cancer 81.6%
75.9–86.5%
 2.8% 1.00 2022 (n=61) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Breast Cancer 81.6%
76.0–85.9%
 2.8% 1.00 2022 (n=61) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Breast Cancer 81.6%
75.5–85.9%
 2.8% 1.00 2022 (n=61) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Breast Cancer 81.6%
75.9–86.5%
 2.8% 1.00 2022 (n=61) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Breast Cancer 81.6%
75.4–87.4%
 2.8% 1.00 2022 (n=61) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Breast Cancer 81.6%
76.0–86.3%
 2.8% 1.00 2022 (n=61) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Breast Cancer 81.6%
76.8–86.8%
 2.8% 1.00 2022 (n=61) 44% ▸
KISQALI
RIBOCICLIB SUCCINATE
 Breast Cancer 81.6%
75.8–85.9%
 2.8% 1.00 2022 (n=61) 44% ▸
KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE
 Breast Cancer 81.6%
75.8–86.7%
 2.8% 1.00 2022 (n=61) 44% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Bladder Cancer 81.0%
75.1–86.4%
 4.5% 1.01 2019 (n=14) 44% ▸
TRUXIMA
RITUXIMAB-ABBS
 Diffuse Large B-Cell Lymphoma 80.8%
75.1–85.9%
 4.2% 1.01 2023 (n=15) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Diffuse Large B-Cell Lymphoma 80.8%
75.0–86.0%
 4.2% 1.01 2023 (n=15) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Diffuse Large B-Cell Lymphoma 80.8%
74.7–86.0%
 4.2% 1.01 2023 (n=15) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Non-Small Cell Lung Cancer 80.6%
73.7–85.1%
 2.8% 1.01 2020 (n=48) 44% ▸
YERVOY
IPILIMUMAB
 Melanoma 80.6%
74.1–85.8%
 2.8% 1.01 2022 (n=8) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Hepatocellular Carcinoma 80.6%
74.2–86.0%
 2.8% 1.01 2022 (n=14) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Non-Small Cell Lung Cancer 80.6%
75.0–85.2%
 2.8% 1.01 2020 (n=48) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Hepatocellular Carcinoma 80.6%
74.5–85.2%
 2.8% 1.01 2022 (n=14) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Non-Small Cell Lung Cancer 80.6%
74.1–84.9%
 2.8% 1.01 2020 (n=48) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Hepatocellular Carcinoma 80.6%
74.7–86.4%
 2.8% 1.01 2022 (n=14) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Non-Small Cell Lung Cancer 80.6%
75.8–85.5%
 2.8% 1.01 2020 (n=48) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Hepatocellular Carcinoma 80.6%
75.3–85.4%
 2.8% 1.01 2022 (n=14) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Non-Small Cell Lung Cancer 80.6%
74.5–85.6%
 2.8% 1.01 2020 (n=48) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Hepatocellular Carcinoma 80.6%
74.3–86.0%
 2.8% 1.01 2022 (n=14) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Non-Small Cell Lung Cancer 80.6%
74.4–85.6%
 2.8% 1.01 2020 (n=48) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Hepatocellular Carcinoma 80.6%
74.0–85.9%
 2.8% 1.01 2022 (n=14) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Non-Small Cell Lung Cancer 80.6%
74.1–85.6%
 2.8% 1.01 2020 (n=48) 44% ▸
TAGRISSO
OSIMERTINIB MESYLATE
 Non-Small Cell Lung Cancer 80.6%
75.4–86.0%
 2.8% 1.01 2020 (n=48) 44% ▸
ALECENSA
ALECTINIB HYDROCHLORIDE
 Non-Small Cell Lung Cancer 80.6%
75.2–85.0%
 2.8% 1.01 2020 (n=48) 44% ▸
VENCLEXTA
VENETOCLAX
 Acute Myeloid Leukemia 80.6%
73.9–85.5%
 2.8% 1.01 — 44% ▸
YERVOY
IPILIMUMAB
 Renal Cell Carcinoma 80.4%
74.7–85.2%
 0.9% 1.01 2022 (n=13) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Renal Cell Carcinoma 80.4%
73.7–85.1%
 0.9% 1.01 2022 (n=13) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Renal Cell Carcinoma 80.4%
74.4–85.7%
 0.9% 1.01 2022 (n=13) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Renal Cell Carcinoma 80.4%
73.9–85.8%
 0.9% 1.01 2022 (n=13) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Renal Cell Carcinoma 80.4%
72.7–84.9%
 0.9% 1.01 2022 (n=13) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Renal Cell Carcinoma 80.4%
74.3–84.6%
 0.9% 1.01 2022 (n=13) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Renal Cell Carcinoma 80.4%
74.6–85.1%
 0.9% 1.01 2022 (n=13) 44% ▸
DARZALEX FASPRO
DARATUMUMAB AND HYALURONIDASE-FIHJ
 Multiple Myeloma 80.4%
74.4–85.2%
 0.9% 1.01 2022 (n=29) 44% ▸
DARZALEX
DARATUMUMAB
 Multiple Myeloma 80.4%
74.4–85.8%
 0.9% 1.01 2022 (n=29) 44% ▸
NINLARO
IXAZOMIB CITRATE
 Multiple Myeloma 80.4%
74.3–85.4%
 0.9% 1.01 2022 (n=29) 44% ▸
EMPLICITI
ELOTUZUMAB
 Multiple Myeloma 80.4%
74.5–86.3%
 0.9% 1.01 2022 (n=29) 44% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Gastric Cancer 80.2%
73.8–84.1%
 1.0% 1.01 2020 (n=66) 44% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Gastric Cancer 80.2%
73.7–85.2%
 1.0% 1.01 2020 (n=66) 44% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Gastric Cancer 80.2%
74.5–85.4%
 1.0% 1.01 2020 (n=66) 44% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Gastric Cancer 80.2%
74.3–85.2%
 1.0% 1.01 2020 (n=66) 44% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Gastric Cancer 80.2%
74.2–84.9%
 1.0% 1.01 2020 (n=66) 44% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Gastric Cancer 80.2%
73.5–84.8%
 1.0% 1.01 2020 (n=66) 44% ▸
HERCESSI
TRASTUZUMAB-STRF
 Gastric Cancer 80.2%
74.8–85.2%
 1.0% 1.01 2020 (n=66) 44% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Gastric Cancer 80.2%
74.8–84.8%
 1.0% 1.01 2020 (n=66) 44% ▸
OGIVRI
TRASTUZUMAB-DKST
 Gastric Cancer 80.2%
72.9–85.0%
 1.0% 1.01 2020 (n=66) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Gastric Cancer 80.2%
74.1–85.2%
 1.0% 1.01 2020 (n=66) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Gastric Cancer 80.2%
73.2–85.4%
 1.0% 1.01 2020 (n=66) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Gastric Cancer 80.2%
73.5–85.3%
 1.0% 1.01 2020 (n=66) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Gastric Cancer 80.2%
73.6–85.1%
 1.0% 1.01 2020 (n=66) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Gastric Cancer 80.2%
74.5–85.1%
 1.0% 1.01 2020 (n=66) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Gastric Cancer 80.2%
75.2–85.0%
 1.0% 1.01 2020 (n=66) 44% ▸
YERVOY
IPILIMUMAB
 Colorectal Cancer 80.0%
73.5–85.4%
 1.3% 1.01 2020 (n=47) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Ovarian Cancer 80.0%
74.6–84.7%
 1.3% 1.01 2020 (n=39) 44% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Colorectal Cancer 80.0%
71.9–84.5%
 1.3% 1.01 2020 (n=47) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Ovarian Cancer 80.0%
73.9–84.9%
 1.3% 1.01 2020 (n=39) 44% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Colorectal Cancer 80.0%
73.6–84.8%
 1.3% 1.01 2020 (n=47) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Ovarian Cancer 80.0%
74.2–85.7%
 1.3% 1.01 2020 (n=39) 44% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Colorectal Cancer 80.0%
74.5–85.1%
 1.3% 1.01 2020 (n=47) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Ovarian Cancer 80.0%
73.9–84.4%
 1.3% 1.01 2020 (n=39) 44% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Colorectal Cancer 80.0%
72.5–84.4%
 1.3% 1.01 2020 (n=47) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Ovarian Cancer 80.0%
73.3–85.5%
 1.3% 1.01 2020 (n=39) 44% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Colorectal Cancer 80.0%
74.2–84.7%
 1.3% 1.01 2020 (n=47) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Ovarian Cancer 80.0%
74.2–85.0%
 1.3% 1.01 2020 (n=39) 44% ▸
MVASI
BEVACIZUMAB-AWWB
 Colorectal Cancer 80.0%
72.6–84.4%
 1.3% 1.01 2020 (n=47) 44% ▸
TRUXIMA
RITUXIMAB-ABBS
 Chronic Lymphocytic Leukemia 80.0%
73.6–84.9%
 1.3% 1.01 2023 (n=20) 44% ▸
RUXIENCE
RITUXIMAB-PVVR
 Chronic Lymphocytic Leukemia 80.0%
73.6–84.6%
 1.3% 1.01 2023 (n=20) 44% ▸
RIABNI
RITUXIMAB-ARRX
 Chronic Lymphocytic Leukemia 80.0%
72.9–85.1%
 1.3% 1.01 2023 (n=20) 44% ▸
VENCLEXTA
VENETOCLAX
 Chronic Lymphocytic Leukemia 80.0%
73.2–84.9%
 1.3% 1.01 2023 (n=20) 44% ▸
PERJETA
PERTUZUMAB
 Breast Cancer 78.6%
72.6–84.3%
 89.0% 1.00 2022 (n=61) 44% ▸
IMFINZI
DURVALUMAB
 Non-Small Cell Lung Cancer 77.5%
71.5–83.0%
 88.0% 1.01 2020 (n=48) 44% ▸
ERBITUX
CETUXIMAB
 Colorectal Cancer 76.8%
69.9–82.2%
 91.3% 1.01 2020 (n=47) 44% ▸
ERBITUX
CETUXIMAB
 Head and Neck Cancer 76.8%
70.2–82.7%
 91.3% 1.01 2023 (n=21) 44% ▸
HERCEPTIN
TRASTUZUMAB
 Breast Cancer 71.6%
63.3–77.2%
 93.0% 1.00 2022 (n=61) 44% ▸
HERCEPTIN
TRASTUZUMAB
 Gastric Cancer 69.6%
62.0–76.1%
 89.0% 1.01 2020 (n=66) 44% ▸
Ibrance
 Breast Cancer 43.5%
34.9–50.8%
 1.8% 0.01 2022 (n=61) 44% ▸
Kisqali
 Breast Cancer 43.5%
35.3–52.0%
 1.8% 0.01 2022 (n=61) 44% ▸
Verzenio
 Breast Cancer 43.5%
34.9–53.3%
 1.8% 0.01 2022 (n=61) 44% ▸
Lynparza
 Breast Cancer 43.5%
33.0–52.4%
 1.8% 0.01 2022 (n=61) 44% ▸
Trodelvy
 Breast Cancer 43.5%
34.5–52.4%
 1.8% 0.01 2022 (n=61) 44% ▸
Enhertu
 Breast Cancer 43.5%
36.3–52.3%
 1.8% 0.01 2022 (n=61) 44% ▸
Kadcyla
 Breast Cancer 43.5%
35.7–52.1%
 1.8% 0.01 2022 (n=61) 44% ▸
Keytruda
 Bladder Cancer 42.5%
33.8–51.5%
 3.8% 0.01 2019 (n=14) 44% ▸
Tecentriq
 Bladder Cancer 42.5%
34.2–50.7%
 3.8% 0.01 2019 (n=14) 44% ▸
Keytruda
 Melanoma 41.9%
34.4–52.1%
 2.1% 0.01 2022 (n=8) 44% ▸
Keytruda
 Non-Small Cell Lung Cancer 41.9%
35.4–51.6%
 2.1% 0.01 2020 (n=48) 44% ▸
Opdivo
 Hepatocellular Carcinoma 41.9%
33.7–48.9%
 2.1% 0.01 2022 (n=14) 44% ▸
Opdivo
 Melanoma 41.9%
33.3–50.1%
 2.1% 0.01 2022 (n=8) 44% ▸
Opdivo
 Non-Small Cell Lung Cancer 41.9%
33.4–50.0%
 2.1% 0.01 2020 (n=48) 44% ▸
Tecentriq
 Non-Small Cell Lung Cancer 41.9%
33.3–50.3%
 2.1% 0.01 2020 (n=48) 44% ▸
Imfinzi
 Non-Small Cell Lung Cancer 41.9%
33.9–49.8%
 2.1% 0.01 2020 (n=48) 44% ▸
Yervoy
 Melanoma 41.9%
33.1–50.3%
 2.1% 0.01 2022 (n=8) 44% ▸
Tagrisso
 Non-Small Cell Lung Cancer 41.9%
32.9–51.5%
 2.1% 0.01 2020 (n=48) 44% ▸
Venclexta
 Acute Myeloid Leukemia 41.9%
34.9–49.8%
 2.1% 0.01 — 44% ▸
Opdivo
 Renal Cell Carcinoma 41.5%
32.4–49.2%
 0.4% 0.01 2022 (n=13) 44% ▸
Darzalex
 Multiple Myeloma 41.5%
33.0–50.7%
 0.4% 0.01 2022 (n=29) 44% ▸
Revlimid
 Multiple Myeloma 41.5%
34.5–51.1%
 0.4% 0.01 2022 (n=29) 44% ▸
Pomalyst
 Multiple Myeloma 41.5%
33.5–49.4%
 0.4% 0.01 2022 (n=29) 44% ▸
Velcade
 Multiple Myeloma 41.5%
33.5–48.9%
 0.4% 0.01 2022 (n=29) 44% ▸
Kyprolis
 Multiple Myeloma 41.5%
33.2–50.4%
 0.4% 0.01 2022 (n=29) 44% ▸
Keytruda
 Gastric Cancer 41.2%
34.2–49.0%
 0.0% 0.01 2020 (n=66) 44% ▸
Enhertu
 Gastric Cancer 41.2%
31.6–49.2%
 0.0% 0.01 2020 (n=66) 44% ▸
Zytiga
 Prostate Cancer 41.2%
33.5–50.2%
 0.0% 0.01 2022 (n=33) 44% ▸
Xtandi
 Prostate Cancer 41.2%
32.6–50.7%
 0.0% 0.01 2022 (n=33) 44% ▸
Nubeqa
 Prostate Cancer 41.2%
33.8–49.3%
 0.0% 0.01 2022 (n=33) 44% ▸
Erleada
 Prostate Cancer 41.2%
34.0–52.0%
 0.0% 0.01 2022 (n=33) 44% ▸
Keytruda
 Head and Neck Cancer 40.9%
33.4–49.0%
 0.0% 0.01 2023 (n=21) 44% ▸
Opdivo
 Head and Neck Cancer 40.9%
32.4–49.8%
 0.0% 0.01 2023 (n=21) 44% ▸
Lynparza
 Ovarian Cancer 40.9%
32.7–49.2%
 0.0% 0.01 2020 (n=39) 44% ▸
Zejula
 Ovarian Cancer 40.9%
31.9–49.1%
 0.0% 0.01 2020 (n=39) 44% ▸
Calquence
 Chronic Lymphocytic Leukemia 40.9%
33.5–49.3%
 0.0% 0.01 2023 (n=20) 44% ▸
Imbruvica
 Chronic Lymphocytic Leukemia 40.9%
33.1–50.8%
 0.0% 0.01 2023 (n=20) 44% ▸
Venclexta
 Chronic Lymphocytic Leukemia 40.9%
34.0–49.1%
 0.0% 0.01 2023 (n=20) 44% ▸
AVASTIN
BEVACIZUMAB
 Breast Cancer 4.5%
3.1–6.7%
 93.0% 1.00 2022 (n=61) 44% ▸
AVASTIN
BEVACIZUMAB
 Hepatocellular Carcinoma 4.2%
2.9–5.8%
 90.0% 1.01 2022 (n=14) 44% ▸
AVASTIN
BEVACIZUMAB
 Non-Small Cell Lung Cancer 4.2%
2.9–5.8%
 90.0% 1.01 2020 (n=48) 44% ▸
AVASTIN
BEVACIZUMAB
 Renal Cell Carcinoma 4.2%
2.9–5.7%
 90.6% 1.01 2022 (n=13) 44% ▸
AVASTIN
BEVACIZUMAB
 Gastric Cancer 4.1%
3.0–5.8%
 91.0% 1.01 2020 (n=66) 44% ▸
AVASTIN
BEVACIZUMAB
 Ovarian Cancer 4.1%
2.9–5.7%
 95.3% 1.01 2020 (n=39) 44% ▸
AVASTIN
BEVACIZUMAB
 Colorectal Cancer 4.1%
2.9–5.7%
 95.3% 1.01 2020 (n=47) 44% ▸